‘Interesting’ Research Continues to Assess the Role of Radiation in Management of Metastatic Kidney Cancer
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, CancerNetwork® spoke with Raquibul Hannan, MD, PhD, a professor in the Department of Radiation Oncology, Urology and Immunology at the University of Texas Southwestern Medical Center in Dallas, about the next steps for researching stereotactic radiation in the management of metastatic kidney cancer.
According to Hannan, future clinical trials in this setting will include the use of procedures like cytoreduction and checkpoint inhibitor immunotherapy to further explore the potential of stereotactic radiation.
“…These are going to be very informative and interesting trials to look forward to,” he said.
Transcript:
There are some interesting ongoing clinical trials that are looking into both the cytoreductive property of stereotactic radiation [and] also the immunogenic potential. The immunogenic potential is something that we have seen in our phase 2 oligoprogressive study, where we saw that patients that are on checkpoint inhibitors getting oligoprogressive [disease] side-treated with stereotactic radiation were doing much better than those that are on [tyrosine kinase inhibitors]. And this is being investigated [in] 2 trials: one of them is called the CYTOSHRINK trial [NCT04090710] by a Canadian group, and the SAMURAI trial [NCT05327686] by NRG, headed by Rana McKay. Both of them are looking to do cytoreduction as well as immune stimulation in the setting of checkpoint inhibitor immunotherapy for patients [with metastatic renal cell carcinoma) who have primary intact, and these are going to be very informative and interesting trials to look forward to.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
